TDP-43 PET Ligand Development for FTD and ALS

TDP-43 PET Ligand Development for FTD and ALS

Background and Rationale

TDP-43 PET Ligand Development for FTD and ALS

Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) represent devastating neurodegenerative diseases with substantial clinical and pathological overlap. Approximately 50% of FTD cases demonstrate TDP-43 proteinopathy as the primary pathological hallmark, while the remaining cases feature tau or FUS inclusions. Similarly, ALS presents with TDP-43 pathology in over 95% of cases, though clinical presentations vary considerably. Currently, in vivo biomarkers capable of distinguishing TDP-43 pathology from other proteinopathies remain unavailable in clinical practice, creating a critical gap in disease characterization and patient stratification for therapeutic trials. This limitation significantly impairs our ability to identify disease subtypes, predict clinical trajectories, and select appropriate candidates for subtype-specific interventions.

...

TDP-43 PET Ligand Development for FTD and ALS

Background and Rationale

TDP-43 PET Ligand Development for FTD and ALS

Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) represent devastating neurodegenerative diseases with substantial clinical and pathological overlap. Approximately 50% of FTD cases demonstrate TDP-43 proteinopathy as the primary pathological hallmark, while the remaining cases feature tau or FUS inclusions. Similarly, ALS presents with TDP-43 pathology in over 95% of cases, though clinical presentations vary considerably. Currently, in vivo biomarkers capable of distinguishing TDP-43 pathology from other proteinopathies remain unavailable in clinical practice, creating a critical gap in disease characterization and patient stratification for therapeutic trials. This limitation significantly impairs our ability to identify disease subtypes, predict clinical trajectories, and select appropriate candidates for subtype-specific interventions. The development of TDP-43-specific positron emission tomography (PET) ligands would directly address this unmet clinical need by enabling non-invasive, in vivo visualization and quantification of pathological TDP-43 accumulation in living patients.

The scientific rationale underlying this proposal stems from the established success of PET neuroimaging in other proteinopathies. Tau PET and amyloid-β PET tracers have substantially advanced Alzheimer's disease research and clinical care by enabling early detection, disease monitoring, and therapeutic efficacy assessment. However, no analogous tools exist for TDP-43 despite its prevalence and clinical significance. TDP-43 exhibits unique biochemical properties that present both opportunities and challenges for ligand development. The protein exists in multiple conformational states within affected neurons, including hyperphosphorylated, ubiquitinated, and aggregated forms that accumulate in pathological inclusions. These post-translational modifications create distinct epitopes amenable to ligand binding. Furthermore, TDP-43 pathology demonstrates relatively selective vulnerability in FTD and ALS, concentrating in layer II of the anterior temporal cortex in FTLD-TDP and motor neurons in ALS, providing anatomically defined target regions for validation. The ability to distinguish TDP-43 from tau pathology would fundamentally transform our diagnostic approach to FTD, as clinical presentation alone remains unreliable for determining underlying proteinopathy. Such distinction would enable recruitment of genetically homogeneous cohorts for clinical trials, potentially explaining the modest effect sizes observed in previous FTD therapeutics studies.

The experimental protocol will employ a multi-phase ligand development strategy. Initial target identification and validation will utilize human neuronal cell lines derived from FTD and ALS patients carrying pathogenic mutations in TARDBP, FUS, C9orf72, and GRN genes, as well as isogenic controls. These cell lines will be differentiated into motor neurons or cortical neurons as appropriate, and treated with established protocols to induce TDP-43 aggregation, including proteasome inhibition, oxidative stress, and overexpression of mutant TDP-43 constructs. Pathological confirmation will employ biochemical fractionation to isolate detergent-insoluble TDP-43 aggregates, followed by characterization via Western blotting, immunofluorescence microscopy, and mass spectrometry to identify phosphorylation sites and other post-translational modifications. These modified epitopes will serve as structural guides for initial medicinal chemistry efforts. Parallel structural studies will utilize cryo-electron microscopy and nuclear magnetic resonance spectroscopy of recombinant TDP-43 and its aggregates to map high-affinity binding sites.

Lead ligand candidates will be synthesized through iterative medicinal chemistry cycles. Initial scaffolds will be derived from existing proteinopathy PET ligands, particularly tau and amyloid tracers, with systematic structural modifications to optimize TDP-43 selectivity and binding affinity. Multiple candidates will undergo in vitro characterization using cell lysates and homogenates from both transgenic mouse models expressing pathological TDP-43 and postmortem brain tissue from neuropathologically confirmed FTLD-TDP and ALS cases. Binding assays will measure dissociation constants, selectivity over tau and other misfolded proteins, and cellular uptake kinetics. Autoradiography studies using postmortem human brain tissue will provide spatial localization validation. Promising candidates will be radiolabeled with fluorine-18 or carbon-11 isotopes and evaluated in mouse models, including transgenic lines expressing human TDP-43 mutations, humanized TDP-43 mice, and transgenic tau and amyloid models as negative controls. Micro-PET imaging will quantify brain uptake, kinetics, and regional specificity across multiple timepoints spanning early, intermediate, and advanced stages of pathology development.

Control conditions will include wild-type littermates, age-matched non-transgenic animals, and transgenic animals with tau or amyloid pathology to establish specificity. Pharmacokinetic studies will measure blood-brain barrier penetration, peripheral kinetics, radiation dosimetry, and metabolite identification. Ex vivo autoradiography of brain sections and immunohistochemical correlation with pathological staging will validate target engagement and establish structure-activity relationships. Toxicology and safety studies in rodents and non-human primates will inform regulatory requirements. Successful lead candidates will proceed to human pilot studies in small cohorts of neuropathologically characterized FTLD-TDP and ALS patients, with healthy controls and tau-positive FTD patients serving as specificity controls.

Expected outcomes include identification of at least two lead TDP-43 PET ligand candidates meeting regulatory criteria for human imaging. These ligands should demonstrate binding affinity in the nanomolar range, excellent blood-brain barrier penetration with brain-to-blood ratios exceeding 3:1, rapid kinetics enabling clinical scanning protocols, metabolic stability with minimal radiometabolite interference, and greater than 5-fold selectivity over tau, amyloid, and other pathological proteins. In vivo imaging should show robust signal in transgenic mouse brains with TDP-43 pathology while exhibiting minimal uptake in control brains. Successful validation would establish that PET signal correlates with TDP-43 pathology burden and regional distribution on neuropathology. Clinical pilot studies should demonstrate feasibility of imaging in living FTD and ALS patients with acceptable safety and tolerability profiles.

Success criteria are defined hierarchically. Primary success requires development of at least one clinical-grade TDP-43 PET ligand meeting FDA regulatory standards and demonstrating specific, quantifiable signal in FTD and ALS patients correlating with disease severity and regional pathology. Secondary success includes establishing proof-of-concept that TDP-43 PET can distinguish FTLD-TDP from FTLD-tau in living patients with diagnostic accuracy exceeding 85% compared to CSF biomarkers or clinical assessment. Tertiary success involves demonstrating that baseline TDP-43 PET burden predicts cognitive decline rates and enables patient stratification for future trials.

Major challenges include the structural complexity of TDP-43 aggregates, which may exist in heterogeneous conformational states with variable epitope accessibility. The lack of established high-resolution structures of pathological TDP-43 aggregates necessitates iterative empirical screening. Off-target binding to RNA or other cellular components may confound signal specificity, requiring rigorous selectivity screening. TDP-43 pathology also localizes to less accessible brain regions, particularly white matter in some cases, potentially limiting imaging contrast. Technical challenges in neuropathological validation arise from the limited availability of well-characterized postmortem tissue with confirmed TDP-43 pathology. Finally, translating successful animal models to humans requires careful consideration of species-specific differences in TDP-43 biology. Despite these challenges, successful development of TDP-43 PET imaging would represent a transformative advance in FTD and ALS precision medicine.

This experiment directly tests predictions arising from the following hypotheses:

• Cryptic Exon Silencing Restoration
• Cross-Seeding Prevention Strategy
• Glycine-Rich Domain Competitive Inhibition
• Axonal RNA Transport Reconstitution
• R-Loop Resolution Enhancement Therapy

Experimental Protocol

Phase 1: Ligand Synthesis and In Vitro Validation (Months 1-6)
• Synthesize candidate TDP-43 PET ligands based on structural analysis of TDP-43 aggregates
• Perform autoradiography on post-mortem brain tissue from FTLD-TDP (n=20), FTLD-tau (n=20), and control subjects (n=10)
• Conduct binding affinity assays using recombinant TDP-43 aggregates (Kd determination)
• Evaluate ligand selectivity against tau, α-synuclein, and amyloid-β aggregates
• Assess blood-brain barrier penetration using in vitro models

Phase 2: Preclinical PET Imaging (Months 7-12)
• Radiolabel lead compounds with [¹¹C] or [¹⁸F] (n=3-5 ligands)
• Perform biodistribution studies in healthy rodents (n=6 per ligand)
• Conduct PET imaging in transgenic TDP-43 mouse models (n=8-10 per group)
• Evaluate pharmacokinetics, brain uptake, and retention patterns
• Perform ex vivo autoradiography correlation with PET signal

Phase 3: Human Safety and Dosimetry (Months 13-18)
• Conduct Phase I safety study in healthy volunteers (n=12)
• Perform whole-body PET scans for radiation dosimetry calculations
• Monitor adverse events and establish maximum tolerated dose
• Evaluate plasma metabolite profiles and kinetic modeling
• Obtain regulatory approvals for patient studies

Phase 4: Clinical Validation Study (Months 19-36)
• Recruit participants: FTLD-TDP (n=30), FTLD-tau (n=30), ALS (n=25), healthy controls (n=25)
• Perform standardized clinical assessments (CDR-FTLD, ALSFRS-R, neuropsychological battery)
• Conduct 90-minute dynamic PET scans with arterial blood sampling
• Obtain structural MRI and CSF biomarkers (pTDP-43, pTau, NfL)
• Perform neuropathological validation in subset with post-mortem tissue (n=10-15)

Phase 5: Data Analysis and Validation (Months 37-42)
• Calculate standardized uptake value ratios (SUVr) using cerebellar reference
• Perform kinetic modeling to derive binding parameters (DVR, BPND)
• Correlate PET signal with clinical severity and progression rates
• Validate diagnostic accuracy using ROC analysis
• Compare with existing CSF and plasma biomarkers

Expected Outcomes

Ligand binding affinity: Lead TDP-43 PET ligand will demonstrate high-affinity binding (Kd < 10 nM) with >10-fold selectivity over tau and amyloid-β aggregates in vitro

Brain penetration: Optimal ligand will achieve brain uptake >2% injected dose/gram at 60 minutes post-injection in preclinical models with appropriate washout kinetics

Diagnostic discrimination: PET imaging will differentiate FTLD-TDP from FTLD-tau with area under the curve (AUC) ≥0.85, showing 2-3 fold higher cortical binding in FTLD-TDP patients

Clinical correlation: TDP-43 PET signal will correlate with disease severity (r ≥ 0.6) and predict clinical progression over 12-month follow-up period

Safety profile: No serious adverse events related to ligand administration in ≥110 total participants across all study phases

Neuropathological validation: Post-mortem tissue analysis will confirm 80-90% agreement between in vivo PET signal and TDP-43 pathology burden assessed by immunohistochemistry

Success Criteria

• Primary endpoint achievement: Demonstrate statistically significant discrimination (p < 0.001) between FTLD-TDP and FTLD-tau patients with effect size (Cohen's d) ≥ 1.2

• Diagnostic accuracy: Achieve sensitivity ≥85% and specificity ≥80% for detecting TDP-43 pathology compared to clinical diagnosis and available biomarkers

• Clinical utility: Establish reliable test-retest reproducibility (ICC ≥ 0.85) and minimal clinically important difference for longitudinal monitoring

• Regulatory compliance: Complete all safety milestones with acceptable radiation dosimetry (<20 mSv effective dose) and no dose-limiting toxicities

• Statistical power: Maintain ≥80% power for primary analyses with completed data from minimum 25 participants per diagnostic group

• Biomarker validation: Demonstrate significant correlation (r ≥ 0.6, p < 0.01) between PET signal and at least two independent TDP-43 biomarkers (CSF pTDP-43, plasma NfL, or neuropathology)